Vertex bows out of hepatitis C race to focus on cystic fibrosis
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals wrote off its experimental hepatitis C drug VX-135, saying the drug has no value, as the company exits a highly competitive field to double down on its cystic fibrosis program.